BRACCO
Website to be confirmed.
About BRACCO
BRACCO is a Radiopharma Developer company; the kind of vendor BD teams should have a 15-minute conversation with at SNMMI.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Endpoints News · 2026-08-25Bracco signs supply agreement to support late-stage trialsDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
- Reuters Health · 2026-07-02Bracco appoints new Chief Medical Officer ahead of pivotal trialIndustry observers expect more activity of this kind in the run-up to SNMMI 2026.
- BioPharma Reporter · 2026-06-07Bracco announces Phase II readout for lead theranostic candidateThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- FierceBiotech · 2026-09-04Bracco expands cyclotron capacity to meet Lu-177 demandCoverage notes the company's growing footprint in the radioligand therapy space.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
Actinium Pharmaceuticals
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Actinium Pharmaceuticals.
View profile →AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →Bayer Oncology
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Bayer Oncology.
View profile →